ATC, representing <1% of thyroid cancers, is reclassified in the fifth WHO edition alongside squamous cell carcinoma, a newly defined subtype sharing follicular cell origin, frequent BRAF mutations, and similarly poor outcomes [96, 170, 189]. This evidence concerns the gene BRAF and thyroid cancer.